Cardio Diagnostics Holdings Inc. (CDIO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CDIO SEC filings page.
Cardio Diagnostics Holdings Inc. (CDIO) reported $14K in revenue over the twelve months to Jun 30, 2026, down 25.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue contracted sharply in FY2025, while a leaner expense base reduced losses but did not bring operations near break-even.
A 57.5% revenue contraction coincided with a 22.5% narrowing in operating loss, indicating cost reduction—not demand growth—drove the reported improvement. Operating cash flow of-$5.7M remained close to the net loss of$6.5M , so the accounting loss largely translated into cash consumption rather than being mainly noncash.
FY2025's current ratio of 9.8x and debt-to-equity ratio of 0.1x describe a lightly leveraged reported balance sheet, but that strength was paired with operating cash flow of
R&D increased from
Financial Health Signals
Cardio Diagnostics Holdings Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cardio Diagnostics Holdings Inc. scores -3.47, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.9M) relative to total liabilities ($793K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cardio Diagnostics Holdings Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Cardio Diagnostics Holdings Inc. reported a net loss of $6.5M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cardio Diagnostics Holdings Inc. reported an operating loss of $6.5M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cardio Diagnostics Holdings Inc. generated $5K in revenue in Q2 2026. This represents a decrease of 28.3% from the same quarter a year earlier. Against the prior quarter it is up 100.0%.
Cardio Diagnostics Holdings Inc.'s EBITDA was -$1.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.6% from the same quarter a year earlier. Against the prior quarter it is up 16.1%.
Cardio Diagnostics Holdings Inc. reported -$1.5M in net income in Q2 2026. This represents an increase of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 16.0%.
Cardio Diagnostics Holdings Inc. earned -$0.51 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 19.0%.
Cash & Balance Sheet
Cardio Diagnostics Holdings Inc. recorded an outflow of $1.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 15.6% from the same quarter a year earlier. Against the prior quarter it is up 14.2%.
Cardio Diagnostics Holdings Inc. held $0 in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Cardio Diagnostics Holdings Inc.'s ROE was -20.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cardio Diagnostics Holdings Inc. invested $163K in research and development in Q2 2026. This represents a decrease of 8.7% from the same quarter a year earlier. Against the prior quarter it is up 25.5%.
Cardio Diagnostics Holdings Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
CDIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K-28.3% | $3K+185.1% | $4K-21.2% | $3K-56.6% | $7K-5.0% | $940-94.1% | $5K | $7K-34.4% |
| R&D Expenses | $163K-8.7% | $130K+9.3% | $155K-24.3% | $189K+3503.0% | $179K+2352.4% | $119K+995.8% | $205K | $5K-86.4% |
| SG&A Expenses | $1.1M-32.1% | $1.5M+13.9% | $347K+279.8% | $1.7M+21.1% | $1.7M+30.7% | $1.3M-69.0% | $91K | $1.4M+2.8% |
| Operating Income | -$1.5M+10.8% | -$1.8M-9.5% | -$1.5M+3.5% | -$1.7M-21.5% | -$1.7M-30.9% | -$1.6M+60.8% | -$1.5M | -$1.4M+2.4% |
| EBITDA | -$1.5M+10.6% | -$1.8M-12.3% | -$1.5M+1.2% | -$1.7M-19.0% | -$1.7M-30.7% | -$1.6M+61.8% | -$1.5M | -$1.4M+2.4% |
| Interest Expense | $3K-26.7% | $3K-26.7% | $2K-26.7% | $3K-19.4% | $5K-19.4% | $5K-19.4% | $3K | $4K-99.3% |
| Net Income | -$1.5M+10.8% | -$1.8M-9.4% | -$1.5M+3.6% | -$1.7M-21.4% | -$1.7M-30.7% | -$1.6M+60.7% | -$1.5M | -$1.4M+26.9% |
| EPS (Basic) | -$0.51+47.4% | -$0.63+35.1% | -$0.80-185.7% | -$0.98+43.4% | -$0.97+43.3% | -$0.97+83.6% | -$0.28 | -$1.73-981.3% |
| EPS (Diluted) | -$0.51 | -$0.63 | -$0.80 | -$0.98 | -$0.97 | -$0.97 | -$0.28 | -$1.73 |
| Diluted Shares (Avg) | 3M | 3M | N/A | 2M | 2M | 2M | N/A | 814,762 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
CDIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.9M-23.8% | $9.6M-22.2% | $7.8M-26.8% | $8.8M+96.1% | $10.4M+160.1% | $12.3M+183.8% | $10.6M+137.9% | $4.5M-24.8% |
| Current Assets | $6.2M-29.2% | $7.7M-26.5% | $5.9M-32.6% | $6.9M+163.7% | $8.7M+307.0% | $10.5M+306.9% | $8.8M+217.9% | $2.6M-41.9% |
| Cash & Equivalents | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $4K-69.8% | $4K-55.3% | $8K-56.3% | $11K-20.4% | $13K+71.9% | $10K-49.7% | $19K+275.2% | $14K+3928.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $500K-25.6% | $656K-27.5% | $793K-25.0% | $637K-19.9% | $672K-27.2% | $905K-29.9% | $1.1M-29.7% | $795K-78.4% |
| Current Liabilities | $359K-2.8% | $491K-9.1% | $605K-4.3% | $398K+29.1% | $370K-1.7% | $541K-21.2% | $632K-24.9% | $309K-89.6% |
| Non-Current Liabilities | $141K-53.5% | $165K-54.8% | $188K-55.8% | $239K-50.9% | $302K-44.7% | $364K-39.8% | $426K-35.8% | $487K-32.5% |
| Total Equity | $7.4M-23.6% | $8.9M-21.7% | $7.0M-27.0% | $8.2M+121.1% | $9.7M+216.3% | $11.4M+274.6% | $9.6M+223.1% | $3.7M+61.1% |
| Retained Earnings | -$32.5M-24.8% | -$31.0M-27.3% | -$29.3M-28.6% | -$27.8M-30.9% | -$26.1M-31.5% | -$24.4M-31.6% | -$22.8M-58.3% | -$21.2M-63.6% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CDIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M+14.6% | -$1.6M-11.6% | -$1.4M+2.2% | -$1.4M-20.4% | -$1.6M-29.8% | -$1.4M-13.5% | -$1.4M+17.4% | -$1.2M-10.8% |
| Depreciation & Amortization | $6K-34.1% | $6K-87.8% | -$29K-643.9% | $40K+741.4% | $8K+77.0% | $45K+848.0% | $5K+11.4% | $5K0.0% |
| Stock-Based Compensation | N/A | $25K-19.2% | N/A | N/A | N/A | $31K-98.8% | N/A | N/A |
| Capital Expenditures | $0-100.0% | $2K-69.6% | $0-100.0% | $163K+600.5% | $19K-88.9% | $6K-71.0% | $4K-99.3% | $23K+84.6% |
| Free Cash Flow | -$1.3M+15.6% | -$1.6M-11.2% | -$1.4M+2.4% | -$1.6M-31.8% | -$1.6M-15.4% | -$1.4M-12.2% | -$1.4M+37.2% | -$1.2M-11.7% |
| Investing Cash Flow | -$47K-31.0% | -$64K-34.3% | -$78K-43.5% | -$258K-228.2% | -$36K+82.2% | -$47K+32.2% | -$55K+90.4% | -$79K+9.8% |
| Financing Cash Flow | -$101K+12.1% | $3.6M+8.6% | $196K-97.3% | $40K-97.9% | -$115K-109.9% | $3.3M+109.1% | $7.3M+7898.7% | $1.9M+774.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CDIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -27950.5% | -66598.4% | -41159.6% | -59950.9% | -22457.5% | -173463.8% | -33608.2% | -21412.9% |
| Net Margin | -28012.5% | -66722.3% | -41219.9% | -60053.8% | -22517.7% | -173943.0% | -33672.6% | -21467.6% |
| Return on Equity | -20.2%-2.9pp | -20.1%-5.7pp | -21.0%-5.1pp | -21.0%+17.3pp | -17.3%+24.6pp | -14.4%+122.7pp | -15.9% | -38.3%+46.2pp |
| Return on Assets | -18.9%-2.8pp | -18.7%-5.4pp | -18.9%-4.6pp | -19.5%+12.0pp | -16.2%+16.0pp | -13.3%+82.9pp | -14.3% | -31.5%+0.9pp |
| Current Ratio | 17.15-6.4x | 15.76-3.7x | 9.79-4.1x | 17.39+8.9x | 23.55+17.9x | 19.49+15.7x | 13.92+10.6x | 8.51+7.0x |
| Debt-to-Equity | 0.070.0x | 0.070.0x | 0.110.0x | 0.08-0.1x | 0.07-0.2x | 0.08-0.3x | 0.11-0.4x | 0.22-1.4x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00 | 0.000.0x |
| FCF Margin | -25044.1% | -58357.2% | -38308.0% | -54509.7% | -21273.1% | -149562.6% | -30938.2% | -17942.3% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cardio Diagnostics Holdings Inc. CDIO | FY2025 | $15K | -$6.5M | N/A | $4.9M | — |
| CERO TERAPEUTICS HLDG INC CERO | FY2025 | N/A | N/A | N/A | $177K | — |
| Adial Pharmaceuticals, Inc ADIL | FY2025 | N/A | N/A | N/A | $9.7M | — |
| PharmaCyte Biotech, Inc. PMCB | FY2026 | $0 | -$19.4M | N/A | $3.8M | — |
| Artelo Biosciences, Inc. ARTL | FY2025 | N/A | -$12.9M | N/A | $1.6M | — |
| BRAINSTORM CELL THERAPUTC BCLI | FY2025 | N/A | N/A | N/A | $12.0M | — |
Where Cardio Diagnostics Holdings Inc. Ranks
Frequently Asked Questions
What is Cardio Diagnostics Holdings Inc.'s annual revenue?
Cardio Diagnostics Holdings Inc. (CDIO) reported $15K in total revenue for fiscal year 2025. This represents a -57.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cardio Diagnostics Holdings Inc.'s revenue growing?
Cardio Diagnostics Holdings Inc. (CDIO) revenue declined by 57.5% year-over-year, from $35K to $15K in fiscal year 2025.
Is Cardio Diagnostics Holdings Inc. profitable?
No, Cardio Diagnostics Holdings Inc. (CDIO) reported a net income of -$6.5M in fiscal year 2025.
What is Cardio Diagnostics Holdings Inc.'s EBITDA?
Cardio Diagnostics Holdings Inc. (CDIO) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cardio Diagnostics Holdings Inc.'s return on equity (ROE)?
Cardio Diagnostics Holdings Inc. (CDIO) has a return on equity of -93.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cardio Diagnostics Holdings Inc.'s free cash flow?
Cardio Diagnostics Holdings Inc. (CDIO) recorded an outflow of $5.9M in free cash flow during fiscal year 2025. This represents a -13.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cardio Diagnostics Holdings Inc.'s operating cash flow?
Cardio Diagnostics Holdings Inc. (CDIO) recorded an outflow of $5.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cardio Diagnostics Holdings Inc.'s total assets?
Cardio Diagnostics Holdings Inc. (CDIO) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cardio Diagnostics Holdings Inc.'s capital expenditures?
Cardio Diagnostics Holdings Inc. (CDIO) invested $187K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cardio Diagnostics Holdings Inc. spend on research and development?
Cardio Diagnostics Holdings Inc. (CDIO) invested $641K in research and development during fiscal year 2025.
What is Cardio Diagnostics Holdings Inc.'s current ratio?
Cardio Diagnostics Holdings Inc. (CDIO) had a current ratio of 9.79 as of fiscal year 2025, which is generally considered healthy.
What is Cardio Diagnostics Holdings Inc.'s debt-to-equity ratio?
Cardio Diagnostics Holdings Inc. (CDIO) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cardio Diagnostics Holdings Inc.'s return on assets (ROA)?
Cardio Diagnostics Holdings Inc. (CDIO) had a return on assets of -83.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cardio Diagnostics Holdings Inc.'s P/E ratio?
Cardio Diagnostics Holdings Inc. (CDIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $4.9M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cardio Diagnostics Holdings Inc.'s price-to-sales ratio?
Cardio Diagnostics Holdings Inc. (CDIO) trades at 342x sales, its market capitalization divided by revenue of $14K revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.9M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Cardio Diagnostics Holdings Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cardio Diagnostics Holdings Inc. (CDIO) held $0 in cash, cash equivalents and investments, and reported an operating cash outflow of $5.7M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cardio Diagnostics Holdings Inc.'s Altman Z-Score?
Cardio Diagnostics Holdings Inc. (CDIO) has an Altman Z-Score of -3.47, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cardio Diagnostics Holdings Inc.'s Piotroski F-Score?
Cardio Diagnostics Holdings Inc. (CDIO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cardio Diagnostics Holdings Inc.'s earnings high quality?
Cardio Diagnostics Holdings Inc. (CDIO) reported a net loss of $6.5M while operations used $5.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cardio Diagnostics Holdings Inc. cover its interest payments?
Cardio Diagnostics Holdings Inc. (CDIO) reported an operating loss of $6.5M against $15K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.